KalVista Pharmaceuticals’ chief development officer sells $19,218 in stock

CAMBRIDGE, MA—Christopher Yea, Chief Development Officer at KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), recently made a notable stock transaction as detailed in a recent SEC filing. On February 24, Yea sold 1,918 shares of KalVista common stock at a price of $10.02 per share, totaling $19,218. This transaction was conducted to cover tax withholding obligations related to the vesting of restricted stock units (RSUs), as per the filing. The stock, currently trading at $10.78, has shown strong momentum with a 27% gain year-to-date, according to InvestingPro data.

Earlier, on February 21, Yea acquired 60,000 restricted stock units, which were converted into common stock with no consideration. Additionally, on February 22, he acquired 3,125 shares through the exercise of RSUs, again with no consideration. Following these transactions, Yea holds a total of 93,952 shares of KalVista common stock. For deeper insights into insider trading patterns and company valuations, InvestingPro subscribers can access 9 additional key tips about KALV’s financial health and market position.

KalVista Pharmaceuticals, a company focused on the development of pharmaceutical preparations, is headquartered in Cambridge, Massachusetts. With a market capitalization of $532 million, the company maintains strong liquidity with a current ratio of 6.87 and holds more cash than debt on its balance sheet.

In other recent news, Kalvista Pharmaceuticals has been making headlines with several noteworthy developments. The company reported receiving Orphan Drug Designation for its drug sebetralstat from Japan’s Ministry of Health, Labour and Welfare, along with submitting a New Drug Application in Japan. This drug, which is aimed at treating hereditary angioedema (HAE), could become the first oral on-demand treatment in the country. Analysts at JMP Securities have maintained a Market Outperform rating for Kalvista, with a price target of $19, highlighting the drug’s potential impact on the HAE market. TD Cowen also initiated coverage with a Buy rating and a higher price target of $30, citing the drug’s potential to exceed $750 million in peak sales. Kalvista’s drug sebetralstat is under regulatory review by the U.S. FDA, with a decision expected by June 17, 2025. The drug has also been submitted for review to the European Medicines Agency and other global authorities. Analysts at JMP Securities noted that the HAE market, valued at approximately $900 million, could significantly expand with the introduction of sebetralstat. Kalvista’s efforts in developing this oral therapy align with the growing patient preference for on-demand treatments over prophylactic options.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.